(Q50973080)

26 March 2018

title

Psoriasis: an evidence-based update. Report of the 9th evidenced based update meeting, 12 May 2011, Loughborough, UK. (English)

1 reference

26 March 2018

author name string

P De Mozzi

series ordinal

1

1 reference

26 March 2018

G A Johnston

series ordinal

2

1 reference

26 March 2018

A B Alexandroff

series ordinal

3

1 reference

26 March 2018

language of work or name

English

0 references

publication date

1 February 2012

1 reference

26 March 2018

British Journal of Dermatology

published in

1 reference

26 March 2018

volume

166

1 reference

26 March 2018

issue

2

1 reference

26 March 2018

page(s)

252-260

1 reference

26 March 2018

Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

A short cycle of narrow-band UVB phototherapy in the early phase of long-term efalizumab can provide a quicker remission of moderate and severe psoriasis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Moral and cost dilemma of a psoriasis patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

A comparison of PUVA-etretinate and PUVA-placebo for palmoplantar pustular psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

The effect of etretinate compared with different regimens of PUVA in the treatment of persistent palmoplantar pustulosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Efficacy of fumaric acid ester monotherapy in psoriasis pustulosa palmoplantaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Management of palmoplantar pustulosis: do we need to change?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Nail psoriasis in Germany: epidemiology and burden of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Finding the missing heritability of complex diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

The IL-23/Th17 axis in the immunopathogenesis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

21 January 2018

Treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Twenty-one years of oral retinoid therapy in siblings with nonbullous ichthyosiform erythroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Psoriasis: an opportunity to identify cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

The risk of mortality in patients with psoriasis: results from a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

More than skin deep: atherosclerosis as a systemic manifestation of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Psoriasis and melanocytic naevi: does the first confer a protective role against melanocyte progression to naevi?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Review of the 90th annual meeting of the british association of dermatologists, 6-8 july 2010, manchester, UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

The role of endothelial cell apoptosis in the effect of etanercept in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Self-management experiences in adults with mild-moderate psoriasis: an exploratory study and implications for improved support.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Report from the 67th annual meeting of the American Academy of Dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

The patient's journey: living with psoriasis - the doctors' perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Narrowband ultraviolet B treatment improves vitamin D balance and alters antimicrobial peptide expression in skin lesions of psoriasis and atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Topical calcitriol restores the impairment of epidermal permeability and antimicrobial barriers induced by corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Safety of antitumour necrosis factor-α therapy in psoriatic patients with hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Epidemiology and comorbidity of psoriasis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Psoriasis and alcohol: is cutaneous ethanol one of the missing links?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Using 'number needed to treat' to express the magnitudes of benefit of ultraviolet B phototherapy and of antitumour necrosis factor-alpha therapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Molecular diagnostics of psoriasis, atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: update of the EDEN Psoriasis Survey 2001-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Socioeconomic disability in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

The expression and phosphorylation of eukaryotic initiation factor 4E are increased in lesional psoriatic skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Alice, Eloi, Magali and Robert: the lives of four patients with psoriasis and the therapeutic approaches of eight European experts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Development and pilot-testing of a psoriasis screening tool.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Itch and scratching as predictors of time to clearance of psoriasis with narrow-band ultraviolet B therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Overweight and childhood psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Delayed generalized inflammatory psoriasis flare during efalizumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

The cystatin M/E-controlled pathway of skin barrier formation: expression of its key components in psoriasis and atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Using 'number needed to treat' to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-alpha inhibitors for patients with severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Upregulation of Fas and downregulation of CD94/NKG2A inhibitory receptors on circulating natural killer cells in patients with new-onset psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Individual differences in the effect of daily stressors on psoriasis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Psoriasis and streptococci: the natural selection of psoriasis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Immunological effects of stress in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Induction of protoporphyrin IX by aminolaevulinic acid in actinic keratosis, psoriasis and normal skin: preferential porphyrin enrichment in differentiated cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Economic evaluation of systemic therapies for moderate to severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Care of patients with psoriasis: an audit of U.K. services in secondary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Inverse relationship between contact allergy and psoriasis: results from a patient- and a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Evaluation of Tonsillectomy as a Treatment for Pustulosis Palmaris Et Plantarts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Is serum amyloid A protein a better indicator of inflammation in severe psoriasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Atherosclerosis as a systemic feature of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

Expression of human leucocyte antigen-G primarily targets affected skin of patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2011.10767.X

10.1111/J.1365-2133.2011.10767.X

21 January 2018

Identifiers

DOI

1 reference

26 March 2018

release_4utcox57wbe4dgo7pkxgpyf244

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4utcox57wbe4dgo7pkxgpyf244

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

26 March 2018